Investing in Stocks Made Easy!
at ₹0 Brokerage with 5paisa.
+91
By proceeding, you agree to all T&C*
Investing in Stocks Made Easy!
We've sent a 6-digit verification code to +91 99123918232
Didn't receive the code? Resend
ARVEE

Arvee Laboratories (India) Share Price

 

 

Arvee Laboratories (India) live price: ₹161. It opened at ₹167 vs previous close ₹164; intraday high/low: ₹167/₹161. The 50 & 200 DMA stand at ₹161.95/₹166.45.

Arvee Laboratories (India) Performance

  • Today's Low
  • ₹161
  • Today's High
  • ₹167
  • 52 Week Low
  • ₹129
  • 52 Week High
  • ₹291
  • Open Price₹167
  • Previous Close₹164
  • Volume233
  • 50 DMA₹161.95
  • 100 DMA₹164.15
  • 200 DMA₹166.45

Arvee Laboratories (India) Chart

Investment Returns

  • Over 1 Month -0.79%
  • Over 3 Month -2.79%
  • Over 6 Month -1.96%
  • Over 1 Year + 8.5%

Smart Investing Starts Here Start SIP with Arvee Laboratories (India) for Steady Growth!

Invest Now

Arvee Laboratories (India) Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 70.2
  • PEG Ratio
  • 4
  • Market Cap Cr
  • 177
  • P/B Ratio
  • 5.3
  • Average True Range
  • 10.1
  • EPS
  • 2.29
  • Dividend Yield
  • 0
  • MACD Signal
  • 1.85
  • RSI
  • 49.05
  • MFI
  • 39.9

Arvee Laboratories (India) Financials

Arvee Laboratories (India) Technicals

EMA & SMA

Current Price
₹161.00
-0.66 (-0.41%)
pointer
  • Bearish Moving Average 12
  • Bullish Moving Average 4
  • 20 Day
  • ₹163.35
  • 50 Day
  • ₹161.95
  • 100 Day
  • ₹164.15
  • 200 Day
  • ₹166.45

Resistance and Support

163.42 Pivot Speed
  • R3 171.24
  • R2 169.22
  • R1 165.44
  • S1 159.64
  • S2 157.62
  • S3 153.84

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Arvee Laboratories (India) has an operating revenue of Rs. 31.51 Cr. on a trailing 12-month basis. An annual revenue de-growth of -18% needs improvement, Pre-tax margin of 8% is okay, ROE of 7% is fair but needs improvement. The company has a reasonable debt to equity of 3%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 200DMA and close to its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 41 which is a POOR score indicating inconsistency in earnings, a RS Rating of 61 which is FAIR indicating the recent price performance, Buyer Demand at C which is evident from recent supply seen, Group Rank of 48 indicates it belongs to a fair industry group of Chemicals-Specialty and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Arvee Laboratories (India) Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-05-19 Audited Results & Others To consider Other business matters. (Revised)
2026-02-13 Quarterly Results & Others To consider Other business matters.
2025-11-13 Quarterly Results
2025-08-12 Quarterly Results
2025-05-09 Audited Results & Others To consider Other business matters.

Arvee Laboratories (India) Shareholding Pattern

73.5%
26.21%
0.29%

Arvee Laboratories (India) FAQs

Arvee Laboratories (India) share price is ₹161 As on 21 May, 2026 | 13:25

The Market Cap of Arvee Laboratories (India) is ₹177.4 Cr As on 21 May, 2026 | 13:25

The P/E ratio of Arvee Laboratories (India) is 70.2 As on 21 May, 2026 | 13:25

The PB ratio of Arvee Laboratories (India) is 5.3 As on 21 May, 2026 | 13:25

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23